Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 12:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1105–1128 of 8,612 matching trials from the live ClinicalTrials.gov search.

Filters: Indianapolis, Indiana Clear all

Conditions: Heart Failure
Interventions: EVAHEART Left Ventricular Assist System (LVAS), HeartMate 3; Device
Lead sponsor: Evaheart, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 12
States / cities: Gainesville, Florida • Tampa, Florida • Indianapolis, Indiana + 9 more

Conditions: Arthroplasty, Replacement, Hip
Interventions: Trident® X3 Polyethylene Insert; Device
Lead sponsor: Stryker Orthopaedics; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 9
States / cities: Atlanta, Georgia • Effingham, Illinois • Indianapolis, Indiana + 6 more

Conditions: Cystic Fibrosis
Interventions: Ivacaftor or elexacaftor/tezacaftor/ivacaftor; Drug
Lead sponsor: Sonya Heltshe; Other
Eligibility: Up to 10 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 31 more

Conditions: Skull Base Neoplasms, Cerebrospinal Fluid Leakage, Nasal; Hypertrophy, Mucous Membrane (Septum)
Interventions: Non-Absorbable Packing (Silastic Splint), PuraGel (RADA16) Hydrogel; Device
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Interventions: Mivelsiran, Placebo; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 40 Years to 55 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Maitland, Florida • Naples, Florida • Indianapolis, Indiana + 1 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: CHICA ADHD Module; Other
Lead sponsor: Indiana University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Idiopathic Pulmonary Fibrosis
Interventions: PRM-151 (Zinpentraxin Alfa), Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 72
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 64 more

Conditions: Age Related Macular Degeneration
Interventions: RBM-007 Injectable Solution; Drug
Lead sponsor: Maturi, Raj K., M.D., P.C.; Individual
Eligibility: 50 Years to 99 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Chronic Graft-versus-host Disease
Interventions: Itacitinib, Placebo, Methylprednisolone, Prednisone; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 39
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 30 more

Conditions: Peripheral T-cell Lymphoma
Interventions: Not listed
Lead sponsor: Acrotech Biopharma Inc.; Industry
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 68
States / cities: Tuscaloosa, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 54 more

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide Fixed Ratio Combination, Insulin glargine (HOE901), Lixisenatide (AVE0010), Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 118
States / cities: Phoenix, Arizona • Tempe, Arizona • Little Rock, Arkansas + 98 more

Conditions: Pancreatic Disease
Interventions: Combined EUS, e-PFT and sEUS Testing; Procedure
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Burns
Interventions: ReCell and Split-thickness skin graft; Device
Lead sponsor: Avita Medical; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 12
States / cities: Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 9 more

Conditions: Hepatitis C, Chronic
Interventions: Not listed
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 6,625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 162
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more

Conditions: Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions: Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 453 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 78
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more

Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Elotuzumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Hollywood, Florida • Peoria, Illinois + 6 more

Conditions: Androgenetic Alopecia
Interventions: PP405 0.05% Topical Gel, Vehicle Topical Gel; Drug
Lead sponsor: Pelage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 57
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Hot Springs, Arkansas + 50 more

Conditions: Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
Interventions: Tovorafenib; Drug
Lead sponsor: Sabine Mueller, MD, PhD; Other
Eligibility: 1 Year to 39 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 15
States / cities: Birmingham, Alabama • San Diego, California • San Francisco, California + 12 more

Conditions: Denture Retention
Interventions: Experimental Denture Adhesive 1, Experimental Denture Adhesive 2, Experimental Denture Adhesive 3, Poligrip Power Hold + Seal; Device
Lead sponsor: HALEON; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Prostate Cancer
Interventions: sipuleucel-T; Biological
Lead sponsor: Dendreon; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 12
States / cities: La Jolla, California • San Diego, California • Washington D.C., District of Columbia + 5 more

Conditions: Healthy
Interventions: LY2541546 - IV, LY2541546 - SC, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 45 Years to 70 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Evansville, Indiana • Indianapolis, Indiana

Conditions: Atopic Dermatitis
Interventions: ASN002; Drug
Lead sponsor: Asana BioSciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 31
States / cities: Anniston, Alabama • Birmingham, Alabama • Fremont, California + 25 more

Conditions: HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
Interventions: ladiratuzumab vedotin, Trastuzumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 38
States / cities: Birmingham, Alabama • Scottsdale, Arizona • La Jolla, California + 30 more

Conditions: Acute Myocardial Infarction
Interventions: Not listed
Lead sponsor: Rohan Dharmakumar; Other
Eligibility: 18 Years and older
Enrollment: 227 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Indianapolis, Indiana

Search by objective public record fields.

Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System

Trident® X3 Polyethylene Insert Study

Study to Evaluate Biological & Clinical Effects of Significantly Corrected CFTR Function in Infants & Young Children

Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery

A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

Using Computers to Assist in the Diagnosis and Treatment of Attention-deficit/Hyperactivity Disorder (ADHD)

A Study to Evaluate the Efficacy and Safety of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis

RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration

GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry

Efficacy and Safety of Insulin Glargine/ Lixisenatide Fixed Ratio Combination Compared to Insulin Glargine Alone and Lixisenatide Alone on Top of Metformin in Patients With T2DM

EUS Ductal Evaluation in One Endoscopic Session for the Diagnosis of Exocrine Pancreas Disease

A Multicenter Comparative Study of the ReCell Device and Autologous Split-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries

Gilead Sustained Virologic Response (SVR) Registry

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Phase 2/3 Efficacy and Safety of PP405 in Adult Males

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

A Clinical Study to Assess the Effectiveness of Use of Three Experimental Denture Adhesives Compared to Using No-Adhesive

To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen

A Study of LY2541546 in Healthy Postmenopausal Women

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

A Safety Study of SGN-LIV1A in Breast Cancer Patients

Hemorrhagic Myocardial Infarction Detection by Post-reperfusion Troponin Kinetics